Date published: 2026-7-4

1-800-457-3801

SCBT Portrait Logo
Seach Input

CYP4A10 CRISPR Activation Plasmid (m): sc-419927-ACT

0.0(0)
Write a reviewAsk a question

Datasheets
  • Target species: mouse
  • 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
  • CYP4A10 CRISPR Activation Plasmid (m) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
  • CYP4A10 CRISPR Activation Plasmid (m) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
  • The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
  • gRNAs encoded by CYP4A10 CRISPR Activation Plasmid (m) and CYP4A10 CRISPR Activation Plasmid (m2) target distinct regulatory regions upstream of the Cyp4a10 transcriptional start site. One or both designs may be available
    Gene Editing Promo Banner

    Ordering Information

    Product NameCatalog #UNITPriceQtyFAVORITES

    CYP4A10 CRISPR Activation Plasmid (m)

    sc-419927-ACT
    20 µg
    $397.00

    Mouse Cyp4a10 encodes the cytochrome P450 enzyme CYP4A10, a microsomal fatty acid ω-hydroxylase that catalyzes metabolism of medium-chain and long-chain fatty acids, including arachidonic acid to bioactive eicosanoids such as 20-HETE. Through these reactions, CYP4A10 contributes to lipid homeostasis and redox balance and can influence signaling networks linked to peroxisome proliferator-activated receptor (PPAR) regulation, renal tubular transport, and vascular tone. Altered Cyp4a10 expression or activity has been associated with dysregulated eicosanoid profiles and downstream effects on blood pressure control, renal physiology, and inflammatory responses. As a result, this gene is frequently studied in metabolic stress models and in pathways connecting lipid oxidation to cardio-renal phenotypes.

    CYP4A10 CRISPR Activation Plasmid (m) provides a targeted, non-destructive approach to upregulating endogenous Cyp4a10 expression without altering the underlying DNA sequence.

    CYP4A10 CRISPR Activation Plasmid (m) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the Cyp4a10 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.

    Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the Cyp4a10 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous CYP4A10 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native Cyp4a10 locus and enabling the study of CYP4A10-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of CYP4A10 pathway restoration in tumor cells with silenced or reduced Cyp4a10 expression.

    For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.